- Home
- BHVN
BHVN
Biohaven Ltd.
as 03-28-2025 4:00pm EST
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 2.9B | IPO Year: | 2017 |
| Target Price: | $63.15 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $26.57 - $55.72 | Next Earning Date: | 03-03-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 379.76% |
Stock Insider Trading Activity of Biohaven Ltd. (BHVN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| CHILDS JOHN W | BHVN | Director | Mar 4 '25 | Buy | $30.64 | 32,700 | $996,238.47 | 2,320,571 | |
| CHILDS JOHN W | BHVN | Director | Dec 30 '24 | Buy | $35.94 | 29,000 | $1,042,393.40 | 2,320,571 |
Latest Biohaven Ltd. News
BHVN Breaking Stock News: Dive into BHVN Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
Insider Monkey
19 days ago
Biohaven Ltd. (BHVN): Among Stocks with Heavy Insider Buying in 2025
TipRanks
21 days ago
Biohaven price target lowered to $63 from $69 at Morgan Stanley
Simply Wall St.
23 days ago
Estimating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)
Investor's Business Daily
24 days ago
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
Zacks
25 days ago
Company News for Mar 4, 2025
PR Newswire
25 days ago
Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
PR Newswire
25 days ago
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results
Compare BHVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BHVN Biohaven Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.